Dates:

18 de setembro, 2020 | 15h00 | Webinar – Plataforma ZOOM

Resumo da apresentação:

 

The human body reacts to injurious stimuli by mounting an inflammatory response. In its acute phase, transvascular extravasation of fluid, plasma proteins and leukocytes occur in the microvasculature of the injured tissue. Inappropriate leukocyte infiltration into tissues associated with stroke, multiple sclerosis, obesity, and other inflammatory disorders have been postulated to cause tissue dysfunction.

The role of vascular endothelial cells as a regulatory organ in immunity and haemostasis has become well established in the last two decades. At sites of injury and inflammation, endothelium becomes locally “activated”. Visualization of leukocyte–endothelial cell interactions in vivo, by intravital microscopy, in inflamed vessels has revealed that leukocytes must first tether and roll along the venule before they can firmly adhere and emigrate out of the vasculature.

The central nervous system is considered an immunologically privileged site due to the presence of the endothelial blood–brain barrier (BBB), which, under physiological conditions, protects against leukocyte traffic into the CNS. However, during inflammatory conditions of the CNS, such as Multiple Sclerosis, large numbers of mononuclear cells gain access to the CNS. Migration of leukocytes through the BBB represents a critical pathogenetic event in the initiation of CNS inflammation.

During the lecture, previous and recent data related to molecular and cellular process (in vivo leukocyte-endothelium interactions) associated to different neuroinflammatory contexts (sepsis and MS) will be presented. The importance of using intravital microscopy technique to understand leukocyte trafficking and other vascular events will be also highlight.


Biography:
She completed her bachelor degree in Immunology & Biochemistry/Biological Sciences/ICB/UFMG and her PhD in Molecular Biology and Physiology Program at Universidad de Valladolid (Valladolid/Spain/Supervisor Dr Mariano Sanchez Crespo). She also was postdoctoral fellow at Cleveland Clinic, Lerner Research Institute (Cleveland, Ohio, USA, Supervisor Dr Damir Janigro); Instituto de Biologia y Genética Molecular (IBGM)/Universidad de Valladolid (Spain/Supervisor Maria Luiza Nieto), and also at Immunology Group/Health Science Centre/University of Calgary (Calgary, Canada/Supervisor Dr Paul Kubes). She is currently Associate Professor IV of the Department of Physiology and Biophysics, and sub-coordinator of the Professional Master's Program in Teaching Biology (PROFBIO) / ICB / UFMG. She got national and international awards at scientific events and from 1st Americas School of Neuroimmunology (ASNI/Calgary, Canada), and also received the title of Honor Professor of XIII Class of Nutrition Undergraduate Course/ UFMG.

She supervised undergraduate, master and PhD, and coordinates and collaborates in scientific projects, mainly in the area of ​​neuroinflammation, publishing the data in indexed international journals, besides chapters and book. She also supervises research projects about Neurosciences and education. She coordinates social AGERE Program (Group of Educational Actions Related to Epilepsy), which received a UFMG recognition as the best Program in the health area (2019). She is permanent member of graduate Program in Physiology and Pharmacology, Graduate Program in Neurosciences, and Professional Master's Program in Teaching Biology (PROFBIO / ICB / UFMG).

 

Registration:

Gratuito
Para assistir basta aceder ao link abaixo, no dia e hora agendada.
Link de acesso: https://zoom.us/j/91672663230
Webinar ID: 916 7266 3230

Organization:

IINFACTS - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde CBAS_4Ed. - Programa Doutoral em Ciências Biológicas Aplicadas à Saúde do IUCS

Dates:

17 de setembro, 2020 | 12h00 | Webinar – Plataforma ZOOM

Resumo da apresentação:

 

Synthetic Cannabinoids (SCs) comprise a diverse group of new psychoactive substances (NPS) that bind and activate cannabinoid receptors (e.g. CB1, CB2) with higher potency than tetrahydrocannabinol (THC, the main psychoactive element of cannabis). Despite being initially designed for therapeutic applications, SCs’ increased potency and longerlasting psychoactive effects compared to THC favored their recreational use. However, SCs also promote stronger adverse effects compared to THC. In fact, the recreational use of SCs has become a major challenge for public health and policy-makers due to the increasing number of SC-related acute intoxications and deaths. SC use by pregnant women and women of child-bearing age is especially alarming due to the potential onset of neurodevelopmental disorders in the offspring. Within the scope of the ongoing NeuroSCANN project, our team has assessed the neurotoxic potential of distinct SCs, particularly focusing on how they affect in vitro neurogenic processes in NG108-15 neuroblastoma x glioma cells, following exposure to SCs at non-toxic, biologically relevant concentrations (≤ 1 nM), either in acute or repeated exposure settings. We reported first-hand that two commonly reported SCs, THJ-2201 and 5F-PB22, enhanced differentiation ratios and total neurite length of NG108-15 cells near 2-fold compared to vehicle-treated cells, in a CB1R activation-dependent way, as CB1 receptor blockade with a specific antagonist abrogated SC-induced effects. Interestingly, at those same concentrations, the SCs tested increased mitochondrial membrane potential but did not affect other toxicological parameters like cell viability, proliferation or intracellular ATP levels. Nevertheless, further research is required to identify the action mechanisms involved in SC-mediated increase of neurodifferentiation.


Biography:
João Pedro Silva (JP Silva) graduated in Applied Biology (2002) at the University of Minho. He further holds an MSc in Molecular Genetics (2004) and a PhD in Biological Sciences (2009) from the same University (Biology Department), having assessed the pharmacological potential of de novo-synthesized antioxidants for oxidative stress-related pathologies. As a Post-Doctoral Researcher (2010-2016), whose work spanned the Centre of Biological Engineering (UMinho), the University Medical Centre Groningen (Netherlands) and University of California Riverside (USA), JP Silva tackled prevailing medical challenges related to wound healing and tuberculosis, having been awarded an Honor Mention in the Bluepharma/UCoimbra 2016 Innovation Award and filing an international patent. Since 2016, JP Silva is a Research Associate at the Toxicology Lab, Faculty of Pharmacy (Univ. Porto) focused on assessing the toxicity of new psychoactive substances (NPS), namely in understanding the role of synthetic cannabinoids in the onset of neurodevelopmental disorders and identify potential therapeutic targets for such pathologies.

Registration:

Gratuito
Para assistir basta aceder ao link abaixo, no dia e hora agendada.
Link de acesso: https://zoom.us/j/91882661979
Webinar ID: 918 8266 1979

Organization:

IINFACTS - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde CBAS_4Ed. - Programa Doutoral em Ciências Biológicas Aplicadas à Saúde do IUCS

Dates:

09 de setembro, 2020 | 12h00 | Webinar – Plataforma ZOOM

Resumo da apresentação:

Melanoma is the deadliest form of skin cancer, and in the last years, incidence has risen faster than almost any other cancer. Targeted therapies, like BRAF and MEK inhibitors, improved the outcome of melanoma patients, however they ultimately develop resistance, promoting the identification of new therapeutic biomarkers.

SPINT2 has been identified as a tumor suppressor gene in various solid tumors and shown to have a role in melanoma aggressiveness, cell migration and proliferation capacity. This protein is a serine protease inhibitor that regulates several cellular functions and signaling pathways, including the HGF/MET pathway. Still, it remains inconclusive how SPINT2 influences melanoma microenvironment, aggressiveness and response to therapy. This presentation will focus on the preliminary results from our group aiming to further understand the tumorigenic role of SPINT2 in melanoma and the influence of this tumor suppressor gene on targeted therapies’ efficiency. Our results propose SPINT2 as a potential therapeutic biomarker towards a more personalized treatment of melanoma patients.


Biography:
Marta Viana-Pereira is a Researcher at Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho and a first-year medical resident at Hospital de Braga. She holds a degree in Applied Biology by the School of Sciences, University of Minho (2005), completed her PhD in Health Sciences by the School of Medicine, University of Minho (2011), awarded with a PhD grant from the Portuguese Science Foundation (FCT), and concluded her Medical Degree by the Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto (2019). During her PhD, Marta was also a visiting research fellow at The Institute of Cancer Research, London, UK (2008-2009). She has 8 years of postdoctoral experience at the School of Medicine, University of Minho (2011-2019). Marta has worked with different tumor models, having acquired a broad experience in the Oncobiology research field, and with the recent Medical Degree she aims to add a clinical significance into her research.

Marta has published several international peer-reviewed research articles and book chapters; supervised 2 Master’s theses and several under-graduated and post-graduated research projects. Her research team has been awarded with several national and international awards.

 

Registration:

Gratuito
Para assistir basta aceder ao link abaixo, no dia e hora agendada.
Link de acesso: https://zoom.us/j/95133692480

Organization:

IINFACTS - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde CBAS_4Ed. - Programa Doutoral em Ciências Biológicas Aplicadas à Saúde do IUCS

Dates:

17 de julho, 2020 | 15h00 | Webinar – Plataforma ZOOM

Resumo da apresentação:

Micro and nanoscale drug delivery strategies have been used to increase drug biodistribution and halflives, control the release rates of drugs, and enable the precise targeting of drugs to biological sites of interest. Drug carriers can range in size from nanoparticles to wearable or implantable macroscale drug reservoirs. However, drug carriers with micro or nanoscale features are particularly attractive, as these carriers can interact with biological systems on the same length scale as cells and cellular processes. While such drug carriers show promise in improving pharmacokinetics and therapeutic outcomes, achieving effective delivery to target sites remains a challenge. To achieve efficient drug release, different types of engineered drug carriers can be formulated with different types of polymer. In this project, different approaches about formulation of controlled release systems will be discussed, since traditional methods of production, microfluidics technique to 3D-printing. 3D-printing of microparticles will provide a pre-programmed delayed and pulsatile drug release profile of an encapsulated therapeutic. The advantage of this technique lies in its ability to access a range of membrane degradation rates from a single polymer matrix material.


Biography:
Flávia Sousa is a Researcher Associate at Imperial College London at Stevens Group in the Department of Materials and Bioengineering. She received her master’s degree in Pharmaceutical Sciences in 2013 at IUCS and in 2019 completed her PhD in Biomedical Sciences, developed at i3S (Porto, Portugal), INL
(International Iberian Nanotechnology Laboratory, Braga, Portugal), Aalborg University (Aalborg, Denmark) and Northeastern University (Boston, USA).
Flávia Sousa is mainly interested in the nanomedicine field, where she built a solid foundation in nanobiomaterials-based nanocarriers for cancer treatment, especially glioblastoma. In the past years, she has accumulated various scientific awards and prestigious recognitions. Also, she is a member of
the Young Committee of Spanish Portuguese Chapter of the Controlled Release Society, member of Young Scientist Committee of Controlled Release Society, first vowel of the Fiscal Council of Portuguese American Postgraduate Society and belongs to a board of CRS Focus Group in Nanomedicine and Nanoscale Delivery as Trainee Representative.

 

Registration:

Gratuito – Inscrição obrigatória em: AQUI

Organization:

IINFACTS - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde CBAS_4Ed. - Programa Doutoral em Ciências Biológicas Aplicadas à Saúde do IUCS

Dates:

4th July, 2019

Organization:

Prof. Júlio Souza
Prof. Hassan Bousbaa

Location:

CESPU, Campus Universitário de Gandra
Auditório 3

Dates:

18th July, 2019

Target audience:

Undergraduate and postgraduate students, teachers, researchers and professionals integrated in CESPU's academic and scientific community.

Prices:

Free.

Location:

CESPU, Cooperativa de Ensino Superior Politécnico e Universitário, crl, Rua Central de Gandra, 1317, 4585-116 Gandra PRD | Portugal

Dates:

09 a 11 de julho, 2019

Registration:

Até 03/06/2019 através de: https://s.up.pt/xy9o

Prices:

Estudantes FFUP (1º, 2º e 3º ciclos) e funcionários FFUP: inscrição é gratuita
Estudantes de 1º e 2º ciclos: 50 Euros
Estudantes de 3º ciclo: 70 Euros
Outros: 90 Euros

Organization:

Laboratório de Química Orgânica e Farmacêutica (LQOF) da FFUP e Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR) em colaboração com i3DU - Medicines and Pharmaceutical Innovation (PhD Programme); IINFACTS; Rotoquímica - Equipamento Científico de Laboratório, Lda

Location:

Anfiteatro 10 do Complexo FFUP/ICBAS

Dates:

04th May, 2019

Training in Good Practices in Clinical Research: for an international ethical and scientific quality in conducting clinical studies in humans.

 

Location:

CESPU, Campus Universitário de Gandra

Dates:

16 de maio, 2019

Prices:

Entrada Gratuita, mas sujeita a inscrição prévia.

Organization:

Professora Doutora Begoña Criado
Professora Doutora Lurdes Teixeira
Professora Doutora Sara Lima
Alunos do 1º ano do CTeSP em Gerontologia 2018/2019

Location:

Auditório da Escola Superior de Saúde do Vale do Ave

Dates:

18th may, 2019

Prices:

Registration Fees

Students - 40€ | Students Basic Fee - 20€ (Only Attendance) | Professionals - 90€ | SOPIO member - 50% discount

Registrations are made through the submission form and the payment by bank transfer.

Fees include lunch, coffee breaks, and the book of abstracts (except the student basic fee) Every attendant is invited to submit an abstract and/or poster without any additional fee.

Location:

Azurém Campus, Minho University
Guimarães - Portugal

Pages